23andMe Holding Cash Flow from Investing Activities 2021-2024 | MEHCQ
23andMe Holding cash flow from investing activities from 2021 to 2024. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
23andMe Holding Annual Cash Flow Investing
(Millions of US $) |
| 2024 |
$-10 |
| 2023 |
$-11 |
| 2022 |
$-108 |
| 2021 |
$-7 |
| 2020 |
$-509 |
| 2020 |
$-73 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.220B |
|
23andMe Inc. is a consumer genetics and research company. It involved in discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory and cardiovascular diseases, in addition to other therapeutic areas. 23andMe Inc., formerly known as VG Acquisition Corp., is headquartered in Sunnyvale, CA.
|
